SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Contact Us
Diabetes
Products
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Skip Navigation Links
Home
»
Investors
»
Press Releases
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
Press Releases
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
8/5/2022
Five-month results from Diamyd
®
trial in LADA published in peer-reviewed scientific journal
7/7/2022
Promising topline results for intralymphatic Diamyd
®
in patients with LADA
6/30/2022
Diamyd Medical joins international consortium in Type 1 Diabetes
6/22/2022
Quarterly Report III 21/22
6/6/2022
Analysis supporting treatment with Diamyd
®
published in peer-reviewed scientific journal
5/30/2022
Immunological analysis of prevention trial with Diamyd
®
published in peer-reviewed scientific journal
5/19/2022
First patient enrolled in Diamyd Medical's Phase III trial DIAGNODE-3
5/9/2022
Diamyd Medical's principal owner transfers half of his holdings in Diamyd Medical to his children
4/29/2022
Diamyd
®
meta-analysis is now available as Open Access publication
4/20/2022
New meta-analysis with Diamyd
®
published in scientific journal
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research